This is a working overview of HGF/c-Met, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Mild to moderate hyperglycemia (typically 130–250 mg/dL, or 7–14 mmol/L) discovered before 25 years of age. However, anyone under 50 can develop MODY. A first-degree relative with a similar degree of diabetes. Absence of positive antibodies or other autoimmunity (e.g., thyroiditis) in patient and family. However, Urbanova et al. found that about one quarter of Central European MODY patients are positive for islet cell autoantibodies (GABA and IA2A). Their expression is transient but highly prevalent. The autoantibodies were found in patients with delayed diabetes onset, and in times of insufficient diabetes control. The islet cell autoantibodies are absent in MODY in at least some populations (Japanese, Britons). Persistence of a low insulin requirement (e.g., less than 0.5 u/kg/day) past the usual "honeymoon" period. Normal insulin levels (e.g. 2.6-24.9) Absence of obesity (although overweight or obese people can get MODY) or other problems associated with type 2 diabetes or metabolic syndrome (e.g., hypertension, hyperlipidemia, polycystic ovary syndrome). Insulin resistance very rarely happens. Cystic kidney disease in patient or close relatives. Non-transient neonatal diabetes, or apparent type 1 diabetes with onset before six months of age. Liver adenoma or hepatocellular carcinoma in MODY type 3 Renal cysts, rudimentary or bicornuate uterus, vaginal aplasia, absence of the vas deferens, epidymal cysts in MODY type 5 The diagnosis of MODY is confirmed by specific gene testing available through commercial laboratories.
== Genetics == The biologic instructions for synthesising protein C in humans are encoded in the gene officially named "protein C (inactivator of coagulation factors Va and VIIIa)". The gene's symbol approved by the HUGO Gene Nomenclature Committee is "PROC" from "protein C". It is located on the second chromosome (2q13-q14) and comprises nine exons. The nucleotide sequence that codes for human protein C is approximately 11,000 bases long.
R = universal gas constant m = number of occupied lattice sites per molecule (for polymer solutions m1 is approximately equal to the degree of polymerization and m2=1) φ = volume fraction of the polymer and the solvent, respectively χ = interaction parameter A consequence of the Flory-Huggins theory is, for instance, that the UCST (if it exists) increases and shifts into the solvent-rich region when the molar mass of the polymer increases. Whether a polymer shows LCST and/or UCST behavior can be derived from the temperature-dependence of the interaction parameter (see figure). The interaction parameter not only comprises enthalpic contributions but also the non-ideal entropy of mixing, which again consists of many individual contributions (e.g., the strong hydrophobic effect in aqueous solutions). For these reasons, classical Flory-Huggins theory cannot provide much insight into the molecular origin of miscibility gaps.
The following twenty years saw a veritable explosion in the number of stability constants that were determined. Relationships, such as the Irving-Williams series were discovered. The calculations were done by hand using the so-called graphical methods. The mathematics underlying the methods used in this period are summarised by Rossotti and Rossotti. The next key development was the use of a computer program, LETAGROP to do the calculations. This permitted the examination of systems too complicated to be evaluated by means of hand-calculations. Subsequently, computer programs capable of handling complex equilibria in general, such as SCOGS and MINIQUAD were developed so that today the determination of stability constants has almost become a "routine" operation. Values of thousands of stability constants can be found in two commercial databases.
CPPs found applications as transporters of contrast agents across plasma membranes. These contrast agents are able to label the tumor cells, making the compounds important tools in cancer diagnosis; they are also used in in vivo and in vitro cellular experiments. The most important classes of CPP are isolated from viruses, such as TAT (transactivated-transcription) derived from HIV-1, penetratin, and transportan. The most widely used CPPs are based on TAT derivatives. TAT is an arginine-rich CPP. Several improvements for this substrate includes the usage of unnatural β or γ amino acids. This strategy offers multiple advantages, such resistance to proteolytic degradation, a natural degradation process by which peptide bonds are hydrolyzed to amino acids. Unnatural acid insertion in the peptide chain has multiple advantages. It facilitates the formation of stable foldamers with distinct secondary structure. β-Peptides are conformationally more stable in aqueous solution than naturally occurring peptides, especially for small chains. The secondary structure is reinforced by the presence of a rigid β-amino acid, which contains cyclohexane or cyclopentane fragments. These fragments generate a more rigid structure and influence the opening angle of the foldamer. These features are important for new peptide design. Helical β-peptides mimic antimicrobial activities of host defense peptides. This feature requires the orientation of cationic –hydrophilic on one side, and hydrophobic residues on the other side of the helix.
Sources: en.wikipedia.org
For example, Lynda Bonewald determined that osteocytes make FGF23, which travels through the bloodstream to trigger the release of phosphorus by the kidneys. Without enough phosphorus bones and teeth soften, and muscles become weak, as in X-linked hypophosphatemia.
== Interactions == Von Willebrand Factor has been shown to interact with Collagen, type I, alpha 1. Recently, It has been reported that the cooperation and interactions within the von Willebrand Factors enhances the adsorption probability in the primary haemostasis. Such cooperation is proven by calculating the adsorption probability of flowing VWF once it crosses another adsorbed one. Such cooperation is held within a wide range of shear rates.
=== Oxides === Two oxides of berkelium are known, with the berkelium oxidation state of +3 (Bk2O3) and +4 (BkO2). Berkelium(IV) oxide is a brown solid, while berkelium(III) oxide is a yellow-green solid with a melting point of 1920 °C and is formed from BkO2 by reduction with molecular hydrogen:
== External links == Weighting cancer drugs to make them hit tumors harder at PhysOrg.com Designing Better Cancer Drugs Insight into Carrier Molecules' Functionality which may yield Safer Cancer Treatments at MIT magazine TechnologyReview.com
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.